Addex Announces Participation in the H.C. Wainwright Global Investment Conference
Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022.
Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex. The presentation will be available for viewing on-demand by registered participants.
Mr. Dyer will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact [email protected].
About Addex Therapeutics:
Addex Forward Looking Statements: